<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962051</url>
  </required_header>
  <id_info>
    <org_study_id>CL07123</org_study_id>
    <nct_id>NCT01962051</nct_id>
  </id_info>
  <brief_title>AMPLATZER Cardiac Plug (ACP) Latin American Post Market Observational</brief_title>
  <acronym>ACP LA</acronym>
  <official_title>AMPLATZER Cardiac Plug (ACP) Latin American Post Market Observational</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ACP device will be clinically evaluated through a prospective, open-label, nonrandomized,&#xD;
      multi-center post market clinical study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    St. Jude Medical business decision&#xD;
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the performance of the ACP device in closure of the LAA</measure>
    <time_frame>2 years post implant</time_frame>
    <description>Defined as absence of flow or flow of â‰¤3mm jet into the LAA at procedure and at 6 months, 1 year and 2 years as assessed by Transoesophageal Echocardiography (TOE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The rate of occurrence for any reported adverse event experienced by subjects enrolled</measure>
    <time_frame>Through 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Left Atrial Appendage</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Delivery system Entry</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amplatzer Cardiac Plug</intervention_name>
    <arm_group_label>Delivery system Entry</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with nonvalvular atrial fibrillation (NVAF)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must have a documented history of paroxysmal, persistent or permanent&#xD;
             nonvalvular atrial fibrillation (documentation may include an electrocardiogram (ECG),&#xD;
             Holter, or event recorder)&#xD;
&#xD;
          -  Subject must have a LAA closure procedure that has already been planned or scheduled&#xD;
             by his/her attending physician before entry in the study&#xD;
&#xD;
          -  Subject must be greater than or equal to 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with an implanted atrial septal defect (ASD) device or patent foramen ovale&#xD;
             (PFO) device&#xD;
&#xD;
          -  Subject underwent LAA closure procedure prior to study entry (i.e. before signing&#xD;
             informed consent&#xD;
&#xD;
          -  Subject who has a history of surgical ASD or PFO repair&#xD;
&#xD;
          -  Subject with a history of stroke and unrepaired PFO&#xD;
&#xD;
          -  Subject who has moderate to severe aortic or mitral valve stenosis or regurgitation&#xD;
             requiring surgical or percutaneous intervention as assessed by the Investigator&#xD;
&#xD;
          -  Subject who has a mitral or aortic prosthetic valve&#xD;
&#xD;
          -  Subject with NYHA grade 4&#xD;
&#xD;
          -  Subject with evidence of moderate pericardial effusion at baseline evaluation&#xD;
&#xD;
          -  Subject who has complex atheroma with mobile plaque of the descending aorta and/or&#xD;
             aortic arch&#xD;
&#xD;
          -  Subject who has an intracardiac thrombus&#xD;
&#xD;
          -  Subject who has carotid disease as assessed by the Investigator, requiring treatment,&#xD;
             which includes revascularization and/or medical treatment&#xD;
&#xD;
          -  Subject with active infection or active endocarditis&#xD;
&#xD;
          -  Subject who has an acute or recent myocardial infarction (MI) or unstable angina&#xD;
             (recent is defined as within 3 months of implant date)&#xD;
&#xD;
          -  Subject who has had recent major cardiac surgical procedure (recent is defined as&#xD;
             within 6 months of implant date)&#xD;
&#xD;
          -  Subject with malignancy or other illness where life expectancy is less than one year&#xD;
&#xD;
          -  Subject who is pregnant, breastfeeding, or desires to become pregnant during their&#xD;
             first six months of follow-up&#xD;
&#xD;
          -  Subject or legally authorized representative who is unable to provide informed consent&#xD;
&#xD;
          -  Subject who will not be able to be followed for the duration of the clinical study&#xD;
&#xD;
          -  Subject with any medical disorder or severe disability that would interfere with&#xD;
             completion or evaluation of clinical study results (for example uncontrolled&#xD;
             hypertension, uncontrolled diabetes, blood disorder, renal failure, in situ IVC&#xD;
             filter)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No data collected as study stopped before sites activated</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

